Resumen
Definición
Anamnesis y examen
Principales factores de diagnóstico
- chronic mood disorder lasting greater than 2 years
- depressive symptoms present for most of the day, most days
- no periods of euthymia in the past 2 years (1 year for children or adolescents)
- symptoms of major depression may be continuously present for 2 or more years
Otros factores de diagnóstico
- no symptoms of mania/hypomania or schizophrenia
- absence of underlying medical conditions, medication use, or substance abuse that could cause the mood disorder
- fatigue or low energy
- low self-esteem
- poor concentration or difficulty making decisions
- feelings of hopelessness
- poor appetite or overeating
- sleep disturbance
Factores de riesgo
- positive family history
- female sex
Pruebas diagnósticas
Primeras pruebas diagnósticas para solicitar
- medical evaluation
- CBC
- thyroid function tests
- metabolic panel
- vitamin D
- Patient Health Questionnaire (PHQ-9)
- Beck Depression Inventory (BDI)
- Quick Inventory of Depressive Symptoms (QIDS)
Pruebas diagnósticas que deben considerarse
- vitamin B12
- urine test
- ECG
Algoritmo de tratamiento
all patients
Colaboradores
Autores
David J. Hellerstein, MD

Professor of Clinical Psychiatry
Columbia University Medical Center
Director, Depression Evaluation Service
New York State Psychiatric Institute
New York
NY
Divulgaciones
DJH has received research grants (through the Research Foundation for Mental Hygiene) from Compass Pathways, Relmada, Marinus, Intracellular Therapies, Beckley Foundation, and from Velocity Foundation (through Columbia University). DJH serves on scientific advisory board for Reset Pharmaceuticals. DJH has received royalties from Johns Hopkins University Press, and Columbia University Press.
Agradecimientos
Dr David J. Hellerstein would like to gratefully acknowledge Dr David L. Dunner, a previous contributor to this topic.
Divulgaciones
DLD has received grant support from Cyberonics. DLD has received fees for consulting from: Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Forest, Cyberonics, Roche Diagnostics, Cypress, Corcept, Janssen, Novartis, Shire, Somerset, Otsuka, Healthcare Technology Sys, Jazz Pharma, Sanofi-Aventis, and MedAvante. DLD is on the Speaker's Bureau for: Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Organon, Jazz Pharma, Neuronetics, and Astra-Zeneca. DLD is an author of several references cited in this topic.
Revisores por pares
Dean F. MacKinnon, MD
Associate Professor
John Hopkins University
Baltimore
MD
Divulgaciones
DK declares that he has no competing interests.
James H. Kocsis, MD
Professor
Weill Cornell Medicine
New York
NY
Divulgaciones
JK has professionally collaborated with the authors.
Neil Nixon, BSc, MMedSci, MBBS, FRCPsych
Associate Professor in Psychiatry
Institute of Mental Health
University of Nottingham
Nottingham
UK
Divulgaciones
NN is a member of the current NICE GDG for depression in adults. NN has met with Jansen in a non-remunerative capacity. He has various research collaborations including a funded trial and is author on a number of papers.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
Referencias
Artículos principales
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
Blanco C, Okuda M, Markowitz JC, et al. The epidemiology of chronic major depressive disorder and dysthymic disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2010 Dec;71(12):1645-56.Texto completo Resumen
Devanand DP, Adorno E, Cheng J, et al. Late onset dysthymic disorder and major depression differ from early onset dysthymic disorder and major depression in elderly outpatients. J Affect Disord. 2004 Mar;78(3):259-67. Resumen
Levkovitz Y, Tedeschini E, Papakostas GI. Efficacy of antidepressants for dysthymia: A meta-analysis of placebo-controlled randomized trials. J Clin Psych. 2011 Apr;72(4):509-14. Resumen
Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007 Apr 18;297(15):1683-96. Resumen
Pedrelli P, Iovieno N, Vitali M, et al. Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis. J Clin Psychopharmacol. 2011 Oct;31(5):582-6. Resumen
Bauer M, Severus E, Köhler S, et al; World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder - update 2015. World J Biol Psychiatry. 2015 Feb;16(2):76-95.Texto completo Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
Diferenciales
- Major depressive disorder
- Bipolar disorders (bipolar I, bipolar II, bipolar disorder not otherwise specified)
- Cyclothymic disorder
Más DiferencialesGuías de práctica clínica
- Screening for depression and suicide risk in adults: US Preventive Services Task Force recommendation statement
- Depression in adults: treatment and management
Más Guías de práctica clínicaFolletos para el paciente
Depression in adults: what is it?
Persistent depressive disorder (long-term depression)
Más Folletos para el pacienteInicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad